When to Run a UGT-Mediated DDI Trial—and Why It Matters Clinically

Sabina Paglialunga, PhD & Aernout van Haarst, PhD, Senior Directors, Scientific Affairs, Celerion Clinical drug–drug interaction (DDI) programs during early drug development are often built around cytochrome P450 (CYP) enzymes and focus on phase I metabolism, but phase II metabolism can be just as consequential for patients. Phase II metabolism involves the conjugation of endogenous […] The post When to Run a UGT-Mediated DDI Trial—and Why It Matters Clinically first appeared on Celerion .